Putting poly (ADP-ribose) polymerase and other DNA repair inhibitors into clinical practice

Current Opinion in Oncology

Volumn 25, Issue 6, 2013, Pages 609-614

  Helleday, Thomas ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

Author keywords

breast cancer; DNA damage; DNA repair; poly (ADP ribose) polymerase

Indexed keywords

ANTINEOPLASTIC AGENT; ANTINEOPLASTIC METAL COMPLEX; BRCA1 PROTEIN; BRCA2 PROTEIN; DNA REPAIR INHIBITOR; DOXORUBICIN; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; PACLITAXEL; RUCAPARIB; TEMOZOLOMIDE; UNCLASSIFIED DRUG;

BREAST CANCER; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CLINICAL PRACTICE; DNA DAMAGE; DNA REPAIR; DRUG EFFICACY; DRUG POTENTIATION; GENOTYPE; GLIOBLASTOMA; GLIOMA; HOMOLOGOUS RECOMBINATION; HUMAN; MELANOMA; MONOTHERAPY; NONHUMAN; ONCOGENE; PRIORITY JOURNAL; REVIEW; TUMOR MICROENVIRONMENT;

ANTINEOPLASTIC AGENTS; DNA DAMAGE; DNA REPAIR; ENZYME INHIBITORS; FEMALE; HUMANS; INDIVIDUALIZED MEDICINE; MALE; MOLECULAR TARGETED THERAPY; MUTATION; NEOPLASMS; POLY(ADP-RIBOSE) POLYMERASES; TREATMENT OUTCOME;

EID: 84885424561     PISSN: 10408746     EISSN: 1531703X     Source Type: Journal    
DOI: 10.1097/CCO.0000000000000016     Document Type: Review

References (45)

1. Luo J, Solimini NL, Elledge SJ. Principles of cancer therapy: oncogene and nononcogene addiction. Cell 2009; 136:823-837.
2. Halazonetis TD, Gorgoulis VG, Bartek J. An oncogene-induced DNA damage model for cancer development. Science 2008; 319:1352-1355.
3. Bartkova J, Rezaei N, Liontos M, et al. Oncogene-induced senescence is part of the tumorigenesis barrier imposed by DNA damage checkpoints. Nature 2006; 444:633-637.
4. Helleday T, Petermann E, Lundin C, et al. DNA repair pathways as targets for cancer therapy. Nat Rev Cancer 2008; 8:193-204.
5. Liu P, Cheng H, Roberts TM, Zhao JJ. Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov 2009; 8:627-644.
6. Chen CC, Taniguchi T, D'Andrea A. The Fanconi anemia (FA) pathway confers glioma resistance to DNA alkylating agents. J Mol Med 2007; 85:497-509.
7. Taniguchi T, Tischkowitz M, Ameziane N, et al. Disruption of the Fanconi anemia-BRCA pathway in cisplatin-sensitive ovarian tumors. Nat Med 2003; 9:568-574.
8. Helleday T. Homologous recombination in cancer development, treatment and development of drug resistance. Carcinogenesis 2010; 31:955-960.
9. Curtin NJ. DNA repair dysregulation from cancer driver to therapeutic target. Nat Rev Cancer 2012; 12:801-817.
10. Willmore E, de Caux S, Sunter NJ, et al. A novel DNA-dependent protein kinase inhibitor, NU7026, potentiates the cytotoxicity of topoisomerase II poisons used in the treatment of leukemia. Blood 2004; 103:4659-4665.
11. Strom CE, Johansson F, Uhlen M, et al. Poly (ADP-ribose) polymerase (PARP) is not involved in base excision repair but PARP inhibition traps a single-strand intermediate. Nucleic Acids Res 2011; 39:3166-3175.
12. Dolan ME, Moschel RC, Pegg AE. Depletion of mammalian O6-alkylguanine-DNA alkyltransferase activitybyO6-benzylguanine providesameanstoevaluate the role of this protein in protection against carcinogenic and therapeutic alkylating agents. Proc Natl Acad Sci U S A 1990; 87:5368-5372.
13. Bryant HE, Schultz N, Thomas HD, et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose)polymerase. Nature 2005; 434:913-917.
14. Farmer H, McCabe N, Lord CJ, et al. Targeting the DNA repair defectinBRCA mutant cells as a therapeutic strategy. Nature 2005; 434:917-921.
15. Fong PC, Boss DS, Yap TA, et al. Inhibition of Poly(ADP-Ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 2009; 361:123-134.
16. Gelmon KA, Tischkowitz M, Mackay H, et al. Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, nonrando-mised study. Lancet Oncol 2011; 12:852-861.
17. Rottenberg S, Jaspers JE, Kersbergen A, et al. High sensitivity of BRCA1-deficient mammary tumorstothe PARP inhibitor AZD2281 alone andincombi-nation with platinum drugs. Proc Natl Acad Sci U S A 2008; 105:17079-17084.
18. Sakai W, Swisher EM, Karlan BY, et al. Secondary mutations as a mechanism of cisplatin resistance inBRCA2-mutated cancers. Nature 2008; 451:1116-1120.
19. Toledo LI, Murga M, Fernandez-Capetillo O. Targeting ATR and Chk1 kinases for cancer treatment: a new model for new (and old) drugs. Mol Oncol 2011; 5:368-373.
20. Hoglund A, Nilsson LM, Muralidharan SV, et al. Therapeutic implications for the induced levels of Chk1 in Myc-expressing cancer cells. Clin Cancer Res 2011; 17:7067-7079.
21. Schoppy DW, Ragland RL, Gilad O, et al. Oncogenic stress sensitizes murine cancers to hypomorphic suppression of ATR. J Clin Invest 2012; 122:241-252.
22. Toledo LI, Murga M, Zur R, et al. A cell-based screen identifies ATR inhibitors with synthetic lethal properties for cancer-associated mutations. Nat Struct Mol Biol 2011; 18:721-727.
23. Murga M, Campaner S, Lopez-Contreras AJ, et al. Exploiting oncogene-induced replicative stress for the selective killing of Myc-driven tumors. Nat Struct Mol Biol 2011; 18:1331-1335.
24. Reaper PM, Griffiths MR, Long JM, et al. Selective killing of ATM-or p53-deficient cancer cells through inhibition ofATR. Nat Chem Biol 2011; 7:428-430.
25. Chalmers AJ. The potential role and application of PARP inhibitors in cancer treatment. Br Med Bull 2009; 89:23-40.
26. Dungey FA, Caldecott KW, Chalmers AJ. Enhanced radiosensitization of human glioma cells by combining inhibition of poly(ADP-ribose) polymerase with inhibition of heat shock protein 90. Mol Cancer Ther 2009; 8:2243-2254.
27. Dungey FA, Loser DA, Chalmers AJ. Replication-dependent radiosensitization of human glioma cells by inhibition of poly(ADP-Ribose) polymerase: mechanisms and therapeutic potential. Int J Radiat Oncol Biol Phys 2008; 72:1188-1197.
28. Biddlestone-Thorpe L, Sajjad M, Rosenberg E, et al. ATM kinase inhibition preferentially sensitizes p53-mutant glioma to ionizing radiation. Clin Cancer Res 2013; 19:3189-3200.
29. Fokas E, Prevo R, Pollard JR, et al. Targeting ATR in vivo using the novel inhibitor VE-822 results in selective sensitization of pancreatic tumors to radiation. Cell Death Dis 2012; 3:e441.
30. Sabharwal A, Middleton MR. Exploiting the role of O6-methylguanine-DNA- methyltransferase (MGMT) in cancer therapy. Curr Opin Pharmacol 2006; 6:355-363.
31. Taniguchi T, D'Andrea AD. Molecular pathogenesis of Fanconi anemia: recent progress. Blood 2006; 107:4223-4233.
32. Yarde DN, Oliveira V, Mathews L, et al. Targeting the Fanconi anemia/BRCA pathway circumvents drug resistance in multiple myeloma. Cancer Res 2009; 69:9367-9375.
33. Murakawa Y, Sonoda E, Barber LJ, et al. Inhibitors of the proteasome suppress homologous DNA recombination in mammalian cells. Cancer Res 2007; 67:8536-8543.
34. Perrault R, Wang H, Wang M, et al. Backup pathways of NHEJ are suppressed by DNA-PK. J Cell Biochem 2004; 92:781-794.
35. Bunting SF, Callen E, Wong N, et al. 53BP1 inhibits homologous recombination in Brca1-deficient cells by blocking resection of DNA breaks. Cell 2010; 141:243-254.
36. Adamo A, Collis SJ, Adelman CA, et al. Preventing nonhomologous end joining suppresses DNA repair defects of Fanconi anemia. Mol Cell 2010; 39:25-35.
37. Johnson N, Li YC, Walton ZE, et al. Compromised CDK1 activity sensitizes BRCA-proficient cancers to PARP inhibition. Nat Med 2011; 17:875-882.
38. Huertas P, Cortes-Ledesma F, Sartori AA, et al. CDK targets Sae2 to control DNA-end resection and homologous recombination. Nature 2008; 455:689-692.
39. Ibrahim YH, Garcia-Garcia C, Serra V, et al. PI3K inhibition impairs BRCA1/2 expression and sensitizes BRCA proficient triple negative breast cancer to PARP inhibition. Cancer Discov 2012; 2:1036-1047.
40. Juvekar A, Burga LN, Hu H, et al. Combining a PI3K inhibitor with a PARP inhibitor provides an effective therapy for a mouse model of BRCA1-related breast cancer. Cancer Discov 2012; 2:1048-1063.
41. Kimbung S, Biskup E, Johansson I, et al. Co-targeting of the PI3K pathway improves the response of BRCA1 deficient breast cancer cells to PARP1 inhibition. Cancer Lett 2012; 319:232-241.
42. Chan N, Pires IM, Bencokova Z, et al. Contextual synthetic lethality of cancer cell kill based on the tumor microenvironment. Cancer Res 2010; 70:8045-8054.
43. Liu X, Shi Y, Maag DX, et al. Iniparib nonselectively modifies cysteine-containing proteins in tumor cells and is not a bona fide PARP inhibitor. Clin Cancer Res 2012; 18:510-523.
44. Patel AG, De Lorenzo SB, Flatten KS, et al. Failure of iniparib to inhibit poly(ADP-Ribose) polymerase in vitro. Clin Cancer Res 2012; 18:1655-1662.
45. Plummer R, Lorigan P, Steven N, et al. A phase II study of the potent PARP inhibitor, Rucaparib (PF-01367338, AG014699), with temozolomide in patients with metastatic melanoma demonstrating evidence of chemopoten-tiation. Cancer Chemother Pharmacol 2013; 71:1191-1199.